Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipid Changes After Switch to Raltegravir in HIV Infected Women
NCT02097108Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- May 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoint: Low-density Lipoprotein Cholesterol Reduction at 12 weeks. Started May 2014; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02097108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097108.